PeptiStar key facts
- Developer of medium-sized molecule pharmaceutical components intended to support drug research, development, and commercial production.
- It has raised $204.9M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Development Bank of Japan, Innovation Network Corporation of Japan, Takenaka, YMC, Asahi Kasei Corporate Venture Capital — 26 tracked in total.
- Status: Privately Held (backing).
Who backs PeptiStar
26+- ·The complete investor list: 26 names
- ·Watch PeptiStar: the Monday email on marks, rounds and moves
PeptiStar funding rounds
No funding rounds for PeptiStar are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
PeptiStar investors
26 investors are on record for PeptiStar, including Development Bank of Japan, Innovation Network Corporation of Japan, Takenaka and YMC.
About PeptiStar
Developer of medium-sized molecule pharmaceutical components intended to support drug research, development, and commercial production. The company provides CMC development, process and analytical method development, GMP-compliant manufacturing, and production scale-up for complex compounds such as peptides, oligonucleotide-based substances, and conjugated drug compounds across discovery, clinical development, and commercial stages, enabling pharmaceutical companies to advance drug candidates and maintain stable and compliant manufacturing supply.
- Sector
- Healthcare
- HQ
- Settsu, Japan
- Founded
- 2017
- Employees
- 100
- Website
- peptistarinc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
PeptiStar doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.